About Akoya Biosciences
Akoya Biosciences has been acquired by Quanterix to create an integrated platform for measuring biomarkers across blood and tissue. The company specializes in spatial biology solutions that enable high-plex spatial proteomics at single-cell resolution. Akoya's product portfolio includes the PhenoCycler-Fusion and PhenoImager platforms, which allow researchers to simultaneously visualize dozens of protein biomarkers in tissue samples. The company offers comprehensive assay panels including the PhenoCode Discovery panels covering immuno-oncology (60 markers), neurobiology, and metabolism, along with specialized software for spatial data analysis including inForm, phenoptr, and Phenochart. These solutions are designed for translational research and clinical workflows, supporting applications in oncology, neurology, immunology, and other therapeutic areas. The technology enables researchers to map tumor microenvironments, characterize immune cell architecture, and understand spatial relationships between cells and biomarkers. Akoya's platforms are built for clinical rigor with validated, reproducible results suitable for biomarker discovery, validation, and companion diagnostics development. The acquisition by Quanterix combines Akoya's tissue-based spatial proteomics capabilities with Quanterix's Simoa ultrasensitive liquid biomarker detection technology, creating a comprehensive solution for biomarker research from bench to bedside.
Mission & Story
Mission
Transforming healthcare through global collaboration and cutting-edge science, empowering researchers worldwide to advance precision health
Clinical Focus
Medical conditions and clinical areas addressed by Akoya Biosciences.
Who It Serves
Milestones & Awards
Recent Milestones
Quanterix completed acquisition of Akoya Biosciences, creating first integrated platform for measuring biomarkers across blood and tissue continuum. Launch of PhenoImager HT 2.0 and PhenoCycler-Fusion 2.0 platforms.
Key Partnerships
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company developing digital diagnostics and therapeutics. Their flagship product, Canvas Dx, is the first FDA-authorized AI-powered diagnostic solution for autism in children ages 1.5-6 years, enabling diagnosis within days instead of months or years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.